Potential claims generally involve medications containing the active ingredient semaglutide or tirzepatide, including Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound
From a pharmacological standpoint, several considerations are relevant: Gastrointestinal effects : Retatrutide, like other GLP-1-based therapies, commonly causes nausea, vomiting, diarrhoea, and reduced appetite
Many patients use Semaglutide for 6-12 months to reach their goal, with ongoing support for weight maintenance
2 Organ-on-chip in the 3D in vitro models framework OoCs allow researchers to model human diseases in the lab using immortalized or donor-derived cells cultured in organ-specific microenvironments
This may be especially beneficial for individuals focused on longevity, athletic performance, or recovery from burnout
When you eat food, your body releases the hormone into your gastrointestinal tract